Japan Prices Sovaldi Well Below U.S.
This article was originally published in PharmAsia News
Executive Summary
Japan has granted a reimbursement price to Gilead's hepatitis C drug Sovaldi as the first all-oral therapy for the disease in the country, with each pill priced well below U.S. levels but still set to cost the national healthcare insurance system upwards of $500.